Consolidated Statements of Shareholders' Equity - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Shares		Common Stock and Capital Surplus	[2]	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Shares issued, beginning of year balance (in shares) at Dec. 31, 2022				1,758
Treasury shares outstanding, beginning of year balance (in shares) at Dec. 31, 2022	[1]				(458)
Beginning of year balance at Dec. 31, 2022		$ 71,769	$ 71,469		$ (31,858)	[1]	$ 48,193		$ 56,398	$ (1,264)	$ 300
Stockholders' Equity [Roll Forward]
Net income		8,368	8,344						8,344		24
Other comprehensive income (loss)		967	967							967
Stock option activity, stock awards and other (in shares)				10
Stock option activity, stock awards and other		795	795				795
Purchase of treasury shares, net of ESPP issuances (in shares)	[1]				(22)
Purchase of treasury shares, net of ESPP issuances		(1,992)	(1,992)		$ (1,980)	[1]	(12)
Common stock dividends		(3,138)	(3,138)						(3,138)
Acquisition of noncontrolling interests		66	0								66
Other increases (decreases) in noncontrolling interests		(199)	16				16				(215)
Shares issued, end of year balance (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2023	[1]				(480)
End of year balance at Dec. 31, 2023		76,636	76,461	$ 18	$ (33,838)	[1]	48,992		61,604	(297)	175
Stockholders' Equity [Roll Forward]
Net income		4,586	4,614						4,614		(28)
Other comprehensive income (loss)		177	177							177
Stock option activity, stock awards and other (in shares)				10
Stock option activity, stock awards and other		700	700				700
Purchase of treasury shares, net of ESPP issuances (in shares)	[1]				(38)
Purchase of treasury shares, net of ESPP issuances		(3,002)	(3,002)		$ (2,980)	[1]	(22)
Common stock dividends		(3,381)	(3,381)						(3,381)
Other increases (decreases) in noncontrolling interests		$ 14	(9)				(9)				23
Shares issued, end of year balance (in shares) at Dec. 31, 2024				1,778
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2024		(518)			(518)	[1]
End of year balance at Dec. 31, 2024		$ 75,730	75,560	$ 18	$ (36,818)	[1]	49,661		62,837	(120)	170
Stockholders' Equity [Roll Forward]
Net income		1,728	1,768						1,768		(40)
Other comprehensive income (loss)		526	526							526
Stock option activity, stock awards and other (in shares)				9
Stock option activity, stock awards and other		741	741				741
ESPP issuances, net of purchase of treasury shares (in shares)	[1]				2
ESPP issuances, net of purchase of treasury shares		28	28		$ 28	[1]
Common stock dividends		(3,409)	(3,409)						(3,409)
Other increases (decreases) in noncontrolling interests		$ 38	0				0				38
Shares issued, end of year balance (in shares) at Dec. 31, 2025				1,787
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2025		(516)			(516)	[1]
End of year balance at Dec. 31, 2025		$ 75,382	$ 75,214	$ 18	$ (36,790)	[1]	$ 50,402		$ 61,196	$ 406	$ 168

[1] Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2025, 2024 and 2023. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2025, 2024 and 2023. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.

[2] Common stock and capital surplus includes the par value of common stock of $18 million as of December 31, 2025, 2024 and 2023.